Mark Lakshmanan

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

The Lancet · 2019 · 2,402 citations

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

The Lancet Diabetes & Endocrinology · 2018 · 527 citations